News

Physicians should consider a myasthenia gravis diagnosis in patients who exhibit symptoms such as dysphagia (difficulty swallowing), dysphonia (difficulty speaking), palatal weakness, or a feeling that the tongue is swollen, according to a case report. The case study, “Misdiagnosis of myasthenia gravis presenting with tongue and palatal weakness,” was…

Hormones produced by adipose (fat) tissue, called adipokines, can help assess the progression and status of myasthenia gravis, researchers suggest. A team at Medical University of Silesia in Poland assessed the association between the levels of different adipokines and clinical factors that characterize myasthenia gravis. The study, “…

Argenx is one step closer to launching a global Phase 3 trial to evaluate the potential of its therapy candidate efgartigimod (ARGX-113) for generalized myasthenia gravis (gMG). Following feedback from the U.S. Food and Drug Administration in June, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan…

Treatment with Lemtrada (alemtuzumab), approved for relapsing-remitting multiple sclerosis, may increase the risk of patients developing other autoimmune diseases including myasthenia gravis, a case report suggests. The report, “Myasthenia gravis following alemtuzumab therapy for multiple sclerosis,” was published in the journal Neurology. A 24-year-old woman…

A new case report describes a rare case of a patient with rapid development and worsening of myasthenia gravis (MG) after a stem cell transplant. The research illustrates the importance of considering MG as a potential complication of transplants. The case study, titled “Myasthenia Gravis Presenting…

The interval between two electrical impulses in neurons correlates with clinical severity and may be a biomarker of juvenile myasthenia gravis (JMG), according to a small study. The recent research, “Serial Stimulated Jitter Analysis in Juvenile Myasthenia Gravis,” was published in the journal Muscle &…

Two subtypes of immune cells, Th22 and Tc22, may be directly involved in the development of myasthenia gravis. The study with that finding, “High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy,” was published in Neuroimmunomodulation. Myasthenia gravis (MG)…

A new, modified method for removal of the thymus (thymectomy) in patients with myasthenia gravis can help achieve complete resection along with minimal scarring, leading to better cosmetic results, a new case report shows. The study, “Modified unilateral video-assisted thoracoscopic extended thymectomy for myasthenia gravis using 5-mm incisions: A case report,” was…

Mutations in the genetic sequence of the IL4R gene can increase the risk of myasthenia gravis in the Chinese Han population, the world’s largest ethnic group, researchers reported. The finding was part of the study “IL-4Rα Polymorphism Is Associated With Myasthenia Gravis in Chinese Han Population”…

A Phase 1 study in healthy volunteers shows that argenx’s efgartigimod (ARGX-113) holds potential as a safe and effective therapy to reduce autoimmune disease-associated antibodies in many disorders, including myasthenia gravis. Findings from the study, “Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans,” were…